My Size, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that My Size, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.0K | Apr 15, 2026 |
| FY2020 | Dec 31, 2020 | $142.0K | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $63.0K | Mar 29, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.36M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $8.26M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $7.00M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $4.46M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $131.0K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $142.0K | Mar 18, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.00M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.32M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.73M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $634.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $131.0K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $140.0K | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $42.0K | Mar 29, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $535.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($4.00M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($6.38M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($8.31M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($10.52M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($6.16M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($5.50M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($5.97M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($5.40M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($4.33M) | Mar 21, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.74M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($3.94M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($6.74M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($8.11M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($10.58M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($6.15M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($5.99M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($5.18M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($5.61M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($2.59M) | Mar 21, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $597.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $429.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $974.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.70M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.25M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.52M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.52M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.11M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $845.0K | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $727.0K | Mar 21, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.14M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($3.09M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($6.11M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($7.29M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($7.30M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($5.68M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($5.42M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($3.60M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($4.14M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($2.16M) | Mar 21, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $7.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $7.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $27.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $23.0K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $16.0K | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $103.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $40.0K | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $16.0K | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $36.0K | Mar 21, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.20M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $10.06M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $8.99M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $9.73M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $12.56M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.57M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $2.96M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $7.12M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $2.42M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.15M | Mar 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.05M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.15M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $4.26M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.19M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.70M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.49M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.91M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.82M | Mar 19, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.16M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $6.91M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $4.74M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $4.54M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $10.86M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $2.08M | Apr 14, 2023 |
| FY2021 | Dec 31, 2019 | $1.05M | Mar 18, 2022 |
| FY2020 | Dec 31, 2018 | $5.29M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | ($1.15M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2016 | $1.53M | Mar 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $640.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $133.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $758.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $1.40M | Mar 27, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($69.73M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($63.88M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($59.88M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($53.50M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($45.19M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($34.67M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($28.51M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($23.02M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($17.05M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($11.64M) | Mar 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.30M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $4.88M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.19M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.10M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.67M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.69M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.20M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $5.14M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.80M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $34.0K | Mar 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (20) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (17) | Apr 14, 2023 |
| FY2020 | Dec 31, 2020 | (1) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | (2) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | (3) | Mar 19, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (20) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Apr 1, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | (3) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | (3) | Mar 19, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.64M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 2.04M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 452,724 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 1.46M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 959,297 | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 7.23M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | 2.09M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 1.99M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 22.24M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | 17.41M | Mar 21, 2018 |